Cafepharma Today

June 20 2025 - Gene therapy faces fresh uncertainty as two more top FDA officials depart
Gene therapy faces fresh uncertainty as two more top FDA officials depart
Eli Lilly (LLY) sees strong demand for Mounjaro in India
A longer ‘winter’: Public funding slowdown heightens pressure on biotech startups
Is DTC pharma advertising coming to an end?
*please scroll down for all the latest news *

Make it like cafepharma, but for different industries. Learn more about CompanyUnderground

Check open job listings in your area
Click here to stay updated on CP happenings

learn about pharmaceutical fraud
learn about the False Claims Act
learn about clinical lab fraud

Current News

submit a press release

How the CDC could change under the next Trump administration
NPR
Friday, November 15, 2024 - 11:04am
tags:
CDC, Donald Trump, restructuring
J&J’s nipocalimab shows promise in Phase II Sjögren’s disease trial
Clinical Trials Arena
Friday, November 15, 2024 - 11:02am
tags:
JNJ, nipocalimab, Sjögren’s syndrome
With RFK Jr. appointment for HHS, biopharma industry could face powerful adversary in government
Fierce Pharma
Thursday, November 14, 2024 - 11:11pm
tags:
Robert F Kennedy Jr., Donald Trump, HHS
Gilead lays off 72 workers in Seattle, plans to shutter R&D support site
Fierce Biotech
Thursday, November 14, 2024 - 11:08pm
tags:
Gilead Sciences, Seattle, R&D, layoffs
Bristol Myers faces renewed, $6.7 billion lawsuit over delayed cancer drug
Yahoo/Reuters
Thursday, November 14, 2024 - 11:06pm
tags:
Bristol Myers Squibb, Celgene, legal, Breyanzi
Eisai wins over European regulators on Alzheimer’s drug Leqembi
BioPharma Dive
Thursday, November 14, 2024 - 10:28pm
tags:
Eisai, Biogen, Leqembi, Alzheimer's disease
FDA approves Danziten, the first nilotinib treatment for Ph+ CML with no mealtime restrictions
CP Wire
Thursday, November 14, 2024 - 10:25pm
tags:
Azurity, Danziten, Ph+ CML, FDA, Novartis, Tasigna
Eli Lilly’s weight-loss drug helps nearly 99% of patients remain diabetes-free
Pharma Live
Thursday, November 14, 2024 - 11:21am
tags:
Eli Lilly, weight loss, tirzepatide, Mounjaro, Zepbound, diabetes
5 Reasons Biogen’s Shares Have Dropped 36% in 2024
BioSpace
Thursday, November 14, 2024 - 11:19am
tags:
Biogen, Leqembi, Qalsody, Skyclary, Zurzuvae, Spinraza
Intelligent gears up for FDA approval of fingerprint drug detection device
Clinical Trials Arena
Thursday, November 14, 2024 - 11:16am
tags:
Intelligent Bio Solutions, FDA, Medtech, fingerprint drug screening
Allogene abandons leukemia plans for CAR-T in wake of Breyanzi approval
Fierce Biotech
Thursday, November 14, 2024 - 11:14am
tags:
Allogene, CAR-T, Breyanzi, cema-cel, relapsed or refractory chronic lymphocytic leukemia
Say goodbye to BeiGene as the oncology biopharma becomes BeOne Medicines in rebrand
Fierce Pharma
Thursday, November 14, 2024 - 11:06am
tags:
BeiGene, BeOne Medicines, rebranding, branding
Merck pays $588M for bispecific to defend Keytruda’s kingdom from emerging threat
Fierce Biotech
Thursday, November 14, 2024 - 10:07am
tags:
Merck, Keytruda, bispecific antibodies, LaNova Medicines
Amgen speaks out about bone density concerns with obesity drug
Clinical Trials Arena
Thursday, November 14, 2024 - 10:06am
tags:
Amgen, obesity, bone density, MariTide
Syncona aims Slingshot at biotech's 'translational gap'
Pharmaphorum
Thursday, November 14, 2024 - 10:05am
tags:
Syncona, UK, academic research, Slingshot Therapeutics, biotech
GSK hails survival data with revived myeloma drug Blenrep
Pharmaphorum
Thursday, November 14, 2024 - 10:03am
tags:
GSK, Blenrep, Multiple Myeloma, clinical trials
Cases hit pre-COVID lows as virus season begins
Axios
Thursday, November 14, 2024 - 10:00am
tags:
COVID-19, Flu, RSV
PTC's brain-delivered gene therapy gets US nod for rare genetic disorder
First Word Pharma
Thursday, November 14, 2024 - 9:59am
tags:
PTC Therapeutics, FDA, Kebilidi, AADC deficiency
BMS, Merck, Amgen and more must look to M&A to offset looming patent lapses: Leerink
Fierce Pharma
Wednesday, November 13, 2024 - 9:49pm
tags:
M&A, Bristol Myers Squibb, Amgen, patent cliffs
Johnson & Johnson Takes the 340B Drug Rebate Fight to Federal Court
MedCity News
Wednesday, November 13, 2024 - 9:48pm
tags:
JNJ, 340B, legal, drug rebates

Pages

Latest CP Wire Articles

Hermes Intelligence Launches to Redefine Pharma Data Solutions [sponsored]
The Evolution of Medical Sales: What’s Changing in 2025?
FDA Scraps Key Vaccine Meetings—What It Means for Manufacturers
FDA approves Danziten, the first nilotinib treatment for Ph+ CML with no mealtime restrictions
Daily U.S. Flu Cases Expected to Nearly Double from Last Year by Late November, Predicts Novel Mathematical Forecasting Tool
PharmaBlock Receives 2024 ACS CMO Excellence in Green Chemistry Award, Marking a Second Consecutive Year of Recognition
Leading Clinical Research Network Centricity Research Acquires North Carolina-based Lucas Research
First-of-Its-Kind Alzheimer’s Disease Simulation Paves Way for Personalized Treatment: Penn State, Duke University Study
Centricity Research Appoints New CEO, CFO to Support Next Phase of Growth
Sermo Barometer Examines Influencers’ Impact on Patient Perceptions of Weight Loss Medications & Preventative Care Technologies

Latest Pharmagather Articles

Stir Bars Can't Be Ignored
In the Pipeline
AI Effects on Drug Patents
In the Pipeline
Mirror Morphine
In the Pipeline
Vaccine Advice, Vandalized
In the Pipeline
Novo Nordisk's Canadian Mistake
In the Pipeline
The Bethesda Declaration
In the Pipeline
Taurine and Aging: Is There Anything to It?
In the Pipeline
Cleaning Up the Medical Literature
In the Pipeline
Not One of Your Easy Crystals
In the Pipeline

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.